Omeros Corporation (OMER) Stock Price & Analysis
Omeros Corporation (OMER) closed at USD 17.88 on Wednesday, October 28, 2026, up 2.23% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 17.88; the Oct 28, 2026 session ranged USD 17.25–17.9 on volume of 604,150 shares. Market capitalization is —, with a 52-week range of USD 6.24–21.24 (NGM). Source: Nexqual, retrieved October 29, 2026 at 07:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OMER.md
Key facts (OMER)
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $2.3M; 3 not under a Rule 10b5-1 plan ($1.5M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +132.8% vs S&P 500 +13.6%; 5Y +185.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.02, revenue estimate $37.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OMER)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$174M | -$163M | -$165M | -$167M | -$123M | -$72.8M |
| Net income | $194M | $47.4M | -$118M | -$157M | -$3.4M | $125M |
| EPS (diluted) | $3.12 | $0.76 | -$1.88 | -$2.70 | -$0.05 | — |
| Free cash flow | -$110M | -$86.6M | $74.3M | -$149M | -$116M | -$68.7M |
| Cash + short-term investments | $157M | $195M | $172M | $90.1M | $172M | — |
| Total debt | $313M | $315M | $213M | $165M | $87.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OMER)
Insider sales (SEC Form 4, open-market, last ~7 months) (OMER)
4 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-22…2026-09-23 | Borges David J. | VP, Finance & CAO | 20,000 | $419K | 100% | Yes (adopted February 10, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-28…2026-08-31 | Cancelmo Peter B | VP, General Counsel | 50,000 | $930K | 99.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-26…2026-08-27 | Hanish Arnold C | Director | 15,000 | $282K | 54.7% | No | Too little history (no open-market trades in 2024 or 2025) |
| 2026-08-21…2026-08-24 | Borges David J. | VP, Finance & CAO | 10,906 | $207K | 100% | Yes (adopted February 10, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-20 | Cable Thomas J. | Director | 15,000 | $277K | 30% | No | Too little history (no open-market trades in 2024 or 2025) |
| 2026-08-13 | Borges David J. | VP, Finance & CAO | 5,000 | $85K | 100% | Yes (adopted February 10, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-22 | Cable Thomas J. | Director | 7,500 | $87K | 17.6% | Yes (adopted June 14, 2024) | Too little history (no open-market trades in 2024 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (OMER)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Cantor Fitzgerald | Reiterated | Overweight | $22 |
| 2026-09-22 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $22 |
Total return (dividends reinvested) (OMER)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +132.8% | +185.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +133.5% | +23.3% |
| Volatility (annualized) | 98.1% | 112.4% |
| Max drawdown | -49.5% (Dec 2025→Jun 2026) | -86.8% (Nov 2021→Oct 2023) |
OMER earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.10 | −$0.33 | Beat +$0.43 | — |
| — | Quarter ended Mar 31, 2026 | $0.57 | −$0.39 | Beat +$0.96 | — |
| — | Quarter ended Dec 31, 2025 | $3.14 | $2.24 | Beat +40.2% | — |
| — | Quarter ended Sep 30, 2025 | −$0.32 | −$0.48 | Beat +33.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
OMER recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 13, 2026 | 8-K | Director or executive officer change, or pay arrangement “On August 12, 2026, the Board of Directors of Omeros Corporation (the "Company" or "we"), upon recommendation of the Nominating and Governance Committee of the Board of Directors, increased the number of its directors to nine and appointed Joseph Schocken as a director, effective immediately. Mr. Schocken's initial term will expire at our 2027 annual meeting of shareholders or his earlier resignation or removal. The Board of Directors also appointed Mr. Schocken to the Audit Committee of the Board of Directors.…” |
| Aug 12, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 12, 2026 | 8-K | Quarterly results |
| Jul 29, 2026 | Schedule 13G/A | BlackRock, Inc.: 8.2% of shares, passive 5%+ holder (amended) |
| Jul 20, 2026 | 8-K | Other material event “As previously disclosed, on July 2, 2026, Omeros Corporation (the "Company") entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the "Notes") under which the Company agreed to repurchase a portion of the outstanding Notes following completion of an averaging period. The Company completed the repurchase of approximately $14.5 million aggregate principal amount of Notes on July 20, 2026, for a total purchase price, inclusive of accrued and unpaid interest…” |
| Jul 6, 2026 | 8-K | Other material event “Expected Completion of Previously Disclosed Note Repurchases As previously disclosed, on June 17, 2026, Omeros Corporation (the "Company") entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the "Notes") under which the Company agreed to repurchase a portion of the outstanding Notes. The applicable averaging period has been completed and the Company expects to complete the repurchase of $16.0 million aggregate principal amount of Notes on July 6, 2026,…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
OMER suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Lonza | “In addition to our agreements with Lonza and Vetter, we utilize a third-party vendor for labelling and final packaging of YARTEMELA finished goods.” |
| Supplier | Vetter Pharma International | “We have a Combined Development and Commercial Supply Agreement, effective May 16, 2018, with Vetter Pharma International, GmbH ("Vetter") under which the process for manufacturing of sterile liquid vials pre-filled with finished YARTEMLEA was developed and validated, and pursuant to which Vetter has agreed to aseptically fill YARTEMLEA in vials for clinical or commercial use.” |
| Partner | Novo Nordisk (NVO) | “● our expectations relating to the Asset Purchase and License Agreement (the "APLA"), by and between Omeros Corporation and Novo Nordisk Health Care AG ("Novo Nordisk"), including Novo Nordisk's anticipated development plans for zaltenibart, anticipated outcomes of such plans and the amounts potentially payable to us under the terms of the APLA;” |
| Partner | Daiichi Sankyo | “For a more detailed description of our agreement with Daiichi Sankyo, see "License and Development Agreements" below.” |
| Partner | Omeros and Novo Nordisk Healthcare | “On November 25, 2025, we completed a transaction (the "Transaction") pursuant to an Asset Purchase and License Agreement ("APLA") between Omeros and Novo Nordisk Healthcare AG ("Novo Nordisk"), dated October 10, 2025, in which Novo Nordisk received exclusive global rights in all indications to develop and commercialize our lead investigational MASP-3 inhibitor, zaltenibart (formerly OMS906), and certain related co…” |
| Partner | Novo Nordisk Health Care | “● our expectations relating to the Asset Purchase and License Agreement (the "APLA"), by and between Omeros Corporation and Novo Nordisk Health Care AG ("Novo Nordisk"), including Novo Nordisk's anticipated development plans for zaltenibart, anticipated outcomes of such plans and the amounts potentially payable to us under the terms of the APLA;” |
| Partner | Johnson & Johnson (JNJ) | “Earlier in his career, Mr. Ghesquiere served in business development and alliance management roles at Aventis Pharmaceuticals (acquired by Sanofi) and worked in product marketing/new product planning at Johnson & Johnson.” |
| Partner | Highbridge Capital Management | “On June 3, 2024, we entered into a Credit Agreement with certain funds managed by Athyrium Capital Management, LP and certain funds managed by Highbridge Capital Management, LLC, as lenders (together with additional lenders from time to time, the "Lenders") and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent.” |
Quoted from the company's 10-K filed Mar 31, 2026.
Companies that name OMER in their SEC reports
| Relationship to OMER | Company | Filing | Sentence |
|---|---|---|---|
| partner | Xencor Inc (XNCR) | 10-K Feb 25, 2026 | “In August 2020, the Company entered into a Technology License Agreement (the "Omeros Agreement") with Omeros Corporation ("Omeros"), pursuant to which the Company granted Omeros rights to use the Company's Xtend Fc technology for certain antibody product candidates, including zaltenibart.” |
OMER analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.02 | $-0.27 | +$0.25 | $37.3M | 2 |
| Next quarter (ends Dec 2026) | $0.07 | $-0.18 | +$0.24 | $51.8M | 2 |
| Current fiscal year (ends Dec 2026) | $0.69 | $0.38 | +81.6% | $127.5M | 2 |
| Next fiscal year (ends Dec 2027) | $1.23 | $-0.15 | +$1.39 | $221.3M | 2 |
Key Statistics (as of October 29, 2026 at 07:24 UTC)
| Price | USD 17.88 |
|---|---|
| Change | ▲ 2.23% (up) |
| Previous Close | USD 17.88 |
| Open | USD 17.88 |
| Day Range | USD 17.25 – 17.9 |
| 52-Week Range | USD 6.24 – 21.24 |
| Volume | 604,150 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (OMER)
Nexqual's technical model rates OMER "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 07:24 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.92 (neutral) |
| vs SMA50 | Below (USD 18.51) |
| MACD | -0.4 (negative) |
Earnings (OMER)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.02 |
| Revenue Estimate | $37.27M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.1 vs est -0.33 ▲ beat |
| 2026-03-31 | USD 0.57 vs est -0.39 ▲ beat |
| 2025-12-31 | USD 3.14 vs est 2.24 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.48 ▲ beat |
Source: Nexqual, October 29, 2026 at 07:24 UTC.
Financials & Fundamentals (OMER)
| Total Revenue | $38.42M |
|---|---|
| Gross Margin | +38.34% |
| Operating Margin | +0.26% |
| Profit Margin | +324.88% |
| Current Ratio | 1.95 |
| Total Cash | $131.95M |
| Total Debt | $296.87M |
Source: Nexqual, October 29, 2026 at 07:24 UTC.
Ownership (OMER)
| Insider Ownership | +4.08% |
|---|---|
| Institutional Ownership | +51.34% |
| Shares Outstanding | 72.39M |
| Float | 69.29M |
| Short % of Float | +16.30% |
Source: Nexqual, October 29, 2026 at 07:24 UTC.
From Omeros Corporation's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- The first FDA-approved product from our portfolio of complement-targeted therapeutics is YARTEMLEA (narsoplimab), a proprietary, patented human monoclonal antibody targeting MASP-2 and the lectin pathway of complement.
- We maintain agreements with potential and existing manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
- We have developed mechanistic, in vivo animal data, and proof-of-concept clinical data indicating that narsoplimab may be an effective therapeutic for ARDS and/or related indications.
- As part of our program to develop complement-targeted therapeutics, we have identified MASP-3, which has been shown to be the key activator of the APC, and we believe that we are the first to make this and related discoveries associated with the APC.
Partnerships
- In accordance with the APLA, at the closing of the Transaction, Omeros and Novo Nordisk entered into a transition services agreement (the "Transition Services Agreement") pursuant to which we are providing certain transition services to Novo Nordisk to facilitate the transfer of the acquired assets and liabilities under the APLA and to provide for the continued operation of relevant studies and program activities during the applicable term.
- Subject to certain exceptions and limitations, Novo Nordisk reimburses us for costs and expenses we incur under the Transition Services Agreement, including third-party costs and expenses, costs associated with delivery of transition services by Omeros personnel on an hourly basis at rates specified in the Transition Services Agreement, and for our inventories of zaltenibart drug substance and product.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to extensive government regulation and the failure to comply with these regulations may have a material adverse effect on our operations and business.
- We may face difficulties from changes to current regulations as well as future legislation.
- We may incur substantial costs as a result of commercial disputes, claims, litigation or other legal proceedings relating to our business operations, especially with regard to patent and other intellectual property rights, and such costs or an adverse outcome in such a proceeding may adversely affect our financial condition, results of operations and/or stock price.
- Product liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc. | USD 7.29 | ▲ 8.48% |
| KPTI | Karyopharm Therapeutics Inc. | USD 0.83 | ▲ 73.33% |
| PTCT | PTC Therapeutics, Inc. | USD 63.02 | ▲ 1.5% |
| MGNX | MacroGenics, Inc. | USD 2.47 | ▲ 1.23% |
| TGTX | TG Therapeutics, Inc. | USD 57.4 | ▲ 1.7% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt